Tiny bone marker study in myeloma ends early
NCT ID NCT04111809
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to track four bone-related markers in the blood and urine of multiple myeloma patients receiving standard bisphosphonate therapy. Only 3 people enrolled before the study was terminated. It was designed to observe changes over 12 months, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Necker Hospital, Adult haematology department
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Diabetes drug metformin could boost myeloma treatment